Mangoceuticals, Inc. (NASDAQ: MGRX) Stock Competitors & Peer Comparison
See MGRX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for MGRX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MGRX | $0.39 | +1.64% | 6.6M | -0.29 | -$1.35 | N/A |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| BTSG | $61.43 | +1.96% | 12.1B | 49.54 | $1.24 | N/A |
| BTSGU | $199.90 | +0.61% | 11.9B | 183.15 | $1.11 | N/A |
| TEM | $64.66 | +4.39% | 11.3B | -129.32 | -$0.50 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| HQY | $98.78 | +0.24% | 8.3B | 23.08 | $4.28 | N/A |
| TXG | $63.22 | +2.55% | 8B | -107.15 | -$0.59 | N/A |
| HNGE | $90.76 | -1.19% | 7B | 48.58 | $1.87 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
Stock Comparison
GE HealthCare Technologies Inc. (NASDAQ: GEHCV)
MGRX vs GEHCV Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas GEHCV's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, MGRX is less volatile compared to GEHCV. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check GEHCV's competition here
BrightSpring Health Services, Inc. Common Stock (NASDAQ: BTSG)
MGRX vs BTSG Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, BTSG has a market cap of 12.1B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while BTSG trades at $61.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas BTSG's P/E ratio is 49.54. In terms of profitability, MGRX's ROE is -1.06%, compared to BTSG's ROE of +0.15%. Regarding short-term risk, MGRX is more volatile compared to BTSG. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check BTSG's competition here
BrightSpring Health Services, Inc. Tangible Equity Unit (NASDAQ: BTSGU)
MGRX vs BTSGU Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, BTSGU has a market cap of 11.9B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while BTSGU trades at $199.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas BTSGU's P/E ratio is 183.15. In terms of profitability, MGRX's ROE is -1.06%, compared to BTSGU's ROE of +0.15%. Regarding short-term risk, MGRX is more volatile compared to BTSGU. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check BTSGU's competition here
Tempus AI, Inc. (NASDAQ: TEM)
MGRX vs TEM Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, TEM has a market cap of 11.3B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while TEM trades at $64.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas TEM's P/E ratio is -129.32. In terms of profitability, MGRX's ROE is -1.06%, compared to TEM's ROE of -0.55%. Regarding short-term risk, MGRX is more volatile compared to TEM. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check TEM's competition here
Signify Health, Inc. (NYSE: SGFY)
MGRX vs SGFY Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas SGFY's P/E ratio is 70.91. In terms of profitability, MGRX's ROE is -1.06%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, MGRX is more volatile compared to SGFY. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check SGFY's competition here
HealthEquity, Inc. (NASDAQ: HQY)
MGRX vs HQY Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, HQY has a market cap of 8.3B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while HQY trades at $98.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas HQY's P/E ratio is 23.08. In terms of profitability, MGRX's ROE is -1.06%, compared to HQY's ROE of +0.11%. Regarding short-term risk, MGRX is more volatile compared to HQY. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check HQY's competition here
10x Genomics, Inc. (NASDAQ: TXG)
MGRX vs TXG Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, TXG has a market cap of 8B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while TXG trades at $63.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas TXG's P/E ratio is -107.15. In terms of profitability, MGRX's ROE is -1.06%, compared to TXG's ROE of -0.09%. Regarding short-term risk, MGRX is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check TXG's competition here
Hinge Health, Inc. (NYSE: HNGE)
MGRX vs HNGE Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, HNGE has a market cap of 7B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while HNGE trades at $90.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas HNGE's P/E ratio is 48.58. In terms of profitability, MGRX's ROE is -1.06%, compared to HNGE's ROE of +0.30%. Regarding short-term risk, MGRX is more volatile compared to HNGE. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check HNGE's competition here
R1 RCM Inc. (NASDAQ: RCM)
MGRX vs RCM Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas RCM's P/E ratio is -102.21. In terms of profitability, MGRX's ROE is -1.06%, compared to RCM's ROE of +0.00%. Regarding short-term risk, MGRX is more volatile compared to RCM. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check RCM's competition here
Doximity, Inc. (NYSE: DOCS)
MGRX vs DOCS Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, DOCS has a market cap of 5.1B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while DOCS trades at $27.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas DOCS's P/E ratio is 17.71. In terms of profitability, MGRX's ROE is -1.06%, compared to DOCS's ROE of +0.17%. Regarding short-term risk, MGRX is more volatile compared to DOCS. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check DOCS's competition here
Waystar Holding Corp. (NASDAQ: WAY)
MGRX vs WAY Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, WAY has a market cap of 5B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while WAY trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas WAY's P/E ratio is 17.27. In terms of profitability, MGRX's ROE is -1.06%, compared to WAY's ROE of +0.04%. Regarding short-term risk, MGRX is more volatile compared to WAY. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check WAY's competition here
Heartflow, Inc. Common Stock (NASDAQ: HTFL)
MGRX vs HTFL Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, HTFL has a market cap of 4.3B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while HTFL trades at $49.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas HTFL's P/E ratio is -24.73. In terms of profitability, MGRX's ROE is -1.06%, compared to HTFL's ROE of -0.42%. Regarding short-term risk, MGRX is less volatile compared to HTFL. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check HTFL's competition here
1Life Healthcare, Inc. (NASDAQ: ONEM)
MGRX vs ONEM Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas ONEM's P/E ratio is -7.77. In terms of profitability, MGRX's ROE is -1.06%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, MGRX is more volatile compared to ONEM. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check ONEM's competition here
Privia Health Group, Inc. (NASDAQ: PRVA)
MGRX vs PRVA Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, PRVA has a market cap of 2.6B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while PRVA trades at $20.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas PRVA's P/E ratio is 98.43. In terms of profitability, MGRX's ROE is -1.06%, compared to PRVA's ROE of +0.00%. Regarding short-term risk, MGRX is more volatile compared to PRVA. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check PRVA's competition here
NextGen Healthcare, Inc. (NASDAQ: NXGN)
MGRX vs NXGN Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas NXGN's P/E ratio is -266.00. In terms of profitability, MGRX's ROE is -1.06%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, MGRX is more volatile compared to NXGN. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check NXGN's competition here
Omnicell, Inc. (NASDAQ: OMCL)
MGRX vs OMCL Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, OMCL has a market cap of 1.6B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while OMCL trades at $34.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas OMCL's P/E ratio is 18.23. In terms of profitability, MGRX's ROE is -1.06%, compared to OMCL's ROE of +0.03%. Regarding short-term risk, MGRX is more volatile compared to OMCL. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check OMCL's competition here
Agiliti, Inc. (NYSE: AGTI)
MGRX vs AGTI Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas AGTI's P/E ratio is -71.79. In terms of profitability, MGRX's ROE is -1.06%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, MGRX is more volatile compared to AGTI. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check AGTI's competition here
Omada Health (NASDAQ: OMDA)
MGRX vs OMDA Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, OMDA has a market cap of 1.3B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while OMDA trades at $22.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas OMDA's P/E ratio is 318.43. In terms of profitability, MGRX's ROE is -1.06%, compared to OMDA's ROE of +0.02%. Regarding short-term risk, MGRX is more volatile compared to OMDA. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check OMDA's competition here
Certara, Inc. (NASDAQ: CERT)
MGRX vs CERT Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, CERT has a market cap of 1.3B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while CERT trades at $8.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas CERT's P/E ratio is 20.33. In terms of profitability, MGRX's ROE is -1.06%, compared to CERT's ROE of -0.07%. Regarding short-term risk, MGRX is more volatile compared to CERT. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check CERT's competition here
GoodRx Holdings, Inc. (NASDAQ: GDRX)
MGRX vs GDRX Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, GDRX has a market cap of 1.2B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while GDRX trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas GDRX's P/E ratio is 11.03. In terms of profitability, MGRX's ROE is -1.06%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, MGRX is more volatile compared to GDRX. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check GDRX's competition here
Teladoc Health, Inc. (NYSE: TDOC)
MGRX vs TDOC Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, TDOC has a market cap of 1.2B. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while TDOC trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas TDOC's P/E ratio is -6.55. In terms of profitability, MGRX's ROE is -1.06%, compared to TDOC's ROE of -0.13%. Regarding short-term risk, MGRX is more volatile compared to TDOC. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check TDOC's competition here
HealthStream, Inc. (NASDAQ: HSTM)
MGRX vs HSTM Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, HSTM has a market cap of 868.9M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while HSTM trades at $29.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas HSTM's P/E ratio is 41.31. In terms of profitability, MGRX's ROE is -1.06%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, MGRX is more volatile compared to HSTM. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check HSTM's competition here
CareCloud, Inc. (NASDAQ: CCLDO)
MGRX vs CCLDO Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while CCLDO trades at $27.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas CCLDO's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, MGRX is more volatile compared to CCLDO. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check CCLDO's competition here
SOPHiA GENETICS S.A. (NASDAQ: SOPH)
MGRX vs SOPH Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, SOPH has a market cap of 696.3M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while SOPH trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas SOPH's P/E ratio is -7.48. In terms of profitability, MGRX's ROE is -1.06%, compared to SOPH's ROE of -1.37%. Regarding short-term risk, MGRX is more volatile compared to SOPH. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check SOPH's competition here
Phreesia, Inc. (NYSE: PHR)
MGRX vs PHR Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, PHR has a market cap of 688M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while PHR trades at $11.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas PHR's P/E ratio is 39.75. In terms of profitability, MGRX's ROE is -1.06%, compared to PHR's ROE of +0.04%. Regarding short-term risk, MGRX is more volatile compared to PHR. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check PHR's competition here
Claritev Corporation (NYSE: CTEV)
MGRX vs CTEV Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, CTEV has a market cap of 664.7M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while CTEV trades at $39.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas CTEV's P/E ratio is -2.29. In terms of profitability, MGRX's ROE is -1.06%, compared to CTEV's ROE of +1.40%. Regarding short-term risk, MGRX is less volatile compared to CTEV. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check CTEV's competition here
MultiPlan Corporation (NYSE: MPLN-WT)
MGRX vs MPLN-WT Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to MPLN-WT's ROE of +1.40%. Regarding short-term risk, MGRX is less volatile compared to MPLN-WT. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check MPLN-WT's competition here
Accolade, Inc. (NASDAQ: ACCD)
MGRX vs ACCD Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas ACCD's P/E ratio is -3.08. In terms of profitability, MGRX's ROE is -1.06%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, MGRX is more volatile compared to ACCD. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check ACCD's competition here
Sharecare, Inc. (NASDAQ: SHCR)
MGRX vs SHCR Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas SHCR's P/E ratio is -3.76. In terms of profitability, MGRX's ROE is -1.06%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, MGRX is more volatile compared to SHCR. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check SHCR's competition here
Evolent Health, Inc. (NYSE: EVH)
MGRX vs EVH Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, EVH has a market cap of 479.7M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while EVH trades at $4.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas EVH's P/E ratio is 32.81. In terms of profitability, MGRX's ROE is -1.06%, compared to EVH's ROE of -0.99%. Regarding short-term risk, MGRX is more volatile compared to EVH. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check EVH's competition here
NRC Health (NASDAQ: NRC)
MGRX vs NRC Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, NRC has a market cap of 478.9M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while NRC trades at $21.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas NRC's P/E ratio is 25.91. In terms of profitability, MGRX's ROE is -1.06%, compared to NRC's ROE of +0.48%. Regarding short-term risk, MGRX is less volatile compared to NRC. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check NRC's competition here
SomaLogic, Inc. (NASDAQ: SLGCW)
MGRX vs SLGCW Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, MGRX's ROE is -1.06%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, MGRX is less volatile compared to SLGCW. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check SLGCW's competition here
SomaLogic, Inc. (NASDAQ: SLGC)
MGRX vs SLGC Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas SLGC's P/E ratio is -3.04. In terms of profitability, MGRX's ROE is -1.06%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, MGRX is less volatile compared to SLGC. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check SLGC's competition here
TruBridge, Inc. (NASDAQ: TBRG)
MGRX vs TBRG Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, TBRG has a market cap of 393.6M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while TBRG trades at $26.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas TBRG's P/E ratio is 9.37. In terms of profitability, MGRX's ROE is -1.06%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, MGRX is more volatile compared to TBRG. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check TBRG's competition here
MultiPlan Corporation (NYSE: MPLN)
MGRX vs MPLN Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas MPLN's P/E ratio is -0.23. In terms of profitability, MGRX's ROE is -1.06%, compared to MPLN's ROE of +1.40%. Regarding short-term risk, MGRX is less volatile compared to MPLN. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check MPLN's competition here
So-Young International Inc. (NASDAQ: SY)
MGRX vs SY Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, SY has a market cap of 370M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while SY trades at $2.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas SY's P/E ratio is -8.55. In terms of profitability, MGRX's ROE is -1.06%, compared to SY's ROE of -0.16%. Regarding short-term risk, MGRX is more volatile compared to SY. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check SY's competition here
Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC)
MGRX vs TRHC Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas TRHC's P/E ratio is -4.27. In terms of profitability, MGRX's ROE is -1.06%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, MGRX is more volatile compared to TRHC. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check TRHC's competition here
Sema4 Holdings Corp. (NASDAQ: SMFR)
MGRX vs SMFR Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas SMFR's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to SMFR's ROE of -0.39%. Regarding short-term risk, MGRX is less volatile compared to SMFR. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check SMFR's competition here
American Well Corporation (NYSE: AMWL)
MGRX vs AMWL Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, AMWL has a market cap of 224.3M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while AMWL trades at $13.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas AMWL's P/E ratio is -2.98. In terms of profitability, MGRX's ROE is -1.06%, compared to AMWL's ROE of -0.33%. Regarding short-term risk, MGRX is more volatile compared to AMWL. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check AMWL's competition here
Spok Holdings, Inc. (NASDAQ: SPOK)
MGRX vs SPOK Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, SPOK has a market cap of 223.1M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while SPOK trades at $10.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas SPOK's P/E ratio is 17.80. In terms of profitability, MGRX's ROE is -1.06%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, MGRX is more volatile compared to SPOK. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check SPOK's competition here
LifeMD, Inc. (NASDAQ: LFMDP)
MGRX vs LFMDP Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, LFMDP has a market cap of 160.2M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while LFMDP trades at $23.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas LFMDP's P/E ratio is -724.19. In terms of profitability, MGRX's ROE is -1.06%, compared to LFMDP's ROE of -1.79%. Regarding short-term risk, MGRX is more volatile compared to LFMDP. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check LFMDP's competition here
OptimizeRx Corp. (NASDAQ: OPRX)
MGRX vs OPRX Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, OPRX has a market cap of 149.2M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while OPRX trades at $7.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas OPRX's P/E ratio is 7.29. In terms of profitability, MGRX's ROE is -1.06%, compared to OPRX's ROE of +0.04%. Regarding short-term risk, MGRX is more volatile compared to OPRX. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check OPRX's competition here
LifeMD, Inc. (NASDAQ: LFMD)
MGRX vs LFMD Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, LFMD has a market cap of 147.5M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while LFMD trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas LFMD's P/E ratio is -6.10. In terms of profitability, MGRX's ROE is -1.06%, compared to LFMD's ROE of -1.79%. Regarding short-term risk, MGRX is more volatile compared to LFMD. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check LFMD's competition here
Computer Programs and Systems, Inc. (NASDAQ: CPSI)
MGRX vs CPSI Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas CPSI's P/E ratio is -183.80. In terms of profitability, MGRX's ROE is -1.06%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, MGRX is less volatile compared to CPSI. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check CPSI's competition here
Health Catalyst, Inc. (NASDAQ: HCAT)
MGRX vs HCAT Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, HCAT has a market cap of 126.4M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while HCAT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas HCAT's P/E ratio is 8.55. In terms of profitability, MGRX's ROE is -1.06%, compared to HCAT's ROE of -1.30%. Regarding short-term risk, MGRX is more volatile compared to HCAT. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check HCAT's competition here
Augmedix, Inc. (NASDAQ: AUGX)
MGRX vs AUGX Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas AUGX's P/E ratio is -4.99. In terms of profitability, MGRX's ROE is -1.06%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, MGRX is more volatile compared to AUGX. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check AUGX's competition here
Definitive Healthcare Corp. (NASDAQ: DH)
MGRX vs DH Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, DH has a market cap of 109.7M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while DH trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas DH's P/E ratio is 4.00. In terms of profitability, MGRX's ROE is -1.06%, compared to DH's ROE of -0.79%. Regarding short-term risk, MGRX is more volatile compared to DH. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check DH's competition here
CareCloud, Inc. (NASDAQ: CCLD)
MGRX vs CCLD Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, CCLD has a market cap of 95.2M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while CCLD trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas CCLD's P/E ratio is 8.62. In terms of profitability, MGRX's ROE is -1.06%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, MGRX is more volatile compared to CCLD. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check CCLD's competition here
SCWorx Corp. (NASDAQ: WORX)
MGRX vs WORX Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, WORX has a market cap of 88M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while WORX trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas WORX's P/E ratio is -6.40. In terms of profitability, MGRX's ROE is -1.06%, compared to WORX's ROE of -0.35%. Regarding short-term risk, MGRX is less volatile compared to WORX. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check WORX's competition here
Forian Inc. (NASDAQ: FORA)
MGRX vs FORA Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while FORA trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas FORA's P/E ratio is -24.11. In terms of profitability, MGRX's ROE is -1.06%, compared to FORA's ROE of -0.17%. Regarding short-term risk, MGRX is more volatile compared to FORA. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check FORA's competition here
CareCloud, Inc. (NASDAQ: CCLDP)
MGRX vs CCLDP Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas CCLDP's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, MGRX is more volatile compared to CCLDP. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check CCLDP's competition here
Science 37 Holdings, Inc. (NASDAQ: SNCE)
MGRX vs SNCE Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas SNCE's P/E ratio is -0.27. In terms of profitability, MGRX's ROE is -1.06%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, MGRX is more volatile compared to SNCE. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check SNCE's competition here
Akili, Inc. (NASDAQ: AKLI)
MGRX vs AKLI Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas AKLI's P/E ratio is -0.71. In terms of profitability, MGRX's ROE is -1.06%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, MGRX is more volatile compared to AKLI. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check AKLI's competition here
OneMedNet Corporation (NASDAQ: ONMD)
MGRX vs ONMD Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, ONMD has a market cap of 34M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while ONMD trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas ONMD's P/E ratio is -3.73. In terms of profitability, MGRX's ROE is -1.06%, compared to ONMD's ROE of +2.35%. Regarding short-term risk, MGRX is less volatile compared to ONMD. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check ONMD's competition here
SHL Telemedicine Ltd. (NASDAQ: SHLT)
MGRX vs SHLT Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas SHLT's P/E ratio is -3.87. In terms of profitability, MGRX's ROE is -1.06%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, MGRX is more volatile compared to SHLT. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check SHLT's competition here
Sharecare, Inc. (NASDAQ: SHCRW)
MGRX vs SHCRW Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, MGRX's ROE is -1.06%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, MGRX is more volatile compared to SHCRW. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check SHCRW's competition here
OneMedNet Corporation (NASDAQ: ONMDW)
MGRX vs ONMDW Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, ONMDW has a market cap of 24.9M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while ONMDW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas ONMDW's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to ONMDW's ROE of +2.35%. Regarding short-term risk, MGRX is less volatile compared to ONMDW. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check ONMDW's competition here
Streamline Health Solutions, Inc. (NASDAQ: STRM)
MGRX vs STRM Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas STRM's P/E ratio is -2.40. In terms of profitability, MGRX's ROE is -1.06%, compared to STRM's ROE of -0.65%. Regarding short-term risk, MGRX is more volatile compared to STRM. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check STRM's competition here
Renalytix Plc (NASDAQ: RNLX)
MGRX vs RNLX Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas RNLX's P/E ratio is -0.33. In terms of profitability, MGRX's ROE is -1.06%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, MGRX is less volatile compared to RNLX. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check RNLX's competition here
MSP Recovery, Inc. (NASDAQ: LIFW)
MGRX vs LIFW Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas LIFW's P/E ratio is -0.02. In terms of profitability, MGRX's ROE is -1.06%, compared to LIFW's ROE of +1.56%. Regarding short-term risk, MGRX is more volatile compared to LIFW. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check LIFW's competition here
Babylon Holdings Limited (NYSE: BBLN)
MGRX vs BBLN Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas BBLN's P/E ratio is -0.04. In terms of profitability, MGRX's ROE is -1.06%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, MGRX is less volatile compared to BBLN. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check BBLN's competition here
ETAO International Co., Ltd. (NASDAQ: ETAO)
MGRX vs ETAO Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas ETAO's P/E ratio is -0.01. In terms of profitability, MGRX's ROE is -1.06%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, MGRX is less volatile compared to ETAO. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check ETAO's competition here
Bullfrog AI Holdings, Inc. Common Stock (NASDAQ: BFRG)
MGRX vs BFRG Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, BFRG has a market cap of 9.1M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while BFRG trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas BFRG's P/E ratio is -1.07. In terms of profitability, MGRX's ROE is -1.06%, compared to BFRG's ROE of -1.50%. Regarding short-term risk, MGRX is less volatile compared to BFRG. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check BFRG's competition here
UpHealth, Inc. (NYSE: UPH-WT)
MGRX vs UPH-WT Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, MGRX is less volatile compared to UPH-WT. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check UPH-WT's competition here
UpHealth, Inc. (NYSE: UPH)
MGRX vs UPH Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas UPH's P/E ratio is -0.07. In terms of profitability, MGRX's ROE is -1.06%, compared to UPH's ROE of -1.05%. Regarding short-term risk, MGRX is less volatile compared to UPH. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check UPH's competition here
Pear Therapeutics, Inc. (NASDAQ: PEARW)
MGRX vs PEARW Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas PEARW's P/E ratio is -0.00. In terms of profitability, MGRX's ROE is -1.06%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, MGRX is less volatile compared to PEARW. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check PEARW's competition here
Pear Therapeutics, Inc. (NASDAQ: PEAR)
MGRX vs PEAR Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas PEAR's P/E ratio is -0.08. In terms of profitability, MGRX's ROE is -1.06%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, MGRX is less volatile compared to PEAR. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check PEAR's competition here
Ontrak, Inc. (NASDAQ: OTRK)
MGRX vs OTRK Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas OTRK's P/E ratio is -0.02. In terms of profitability, MGRX's ROE is -1.06%, compared to OTRK's ROE of -2.11%. Regarding short-term risk, MGRX is more volatile compared to OTRK. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check OTRK's competition here
CareMax, Inc. (NASDAQ: CMAX)
MGRX vs CMAX Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas CMAX's P/E ratio is -0.00. In terms of profitability, MGRX's ROE is -1.06%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, MGRX is more volatile compared to CMAX. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check CMAX's competition here
Bullfrog AI Holdings, Inc. Warrants (NASDAQ: BFRGW)
MGRX vs BFRGW Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, BFRGW has a market cap of 1.4M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while BFRGW trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas BFRGW's P/E ratio is -0.92. In terms of profitability, MGRX's ROE is -1.06%, compared to BFRGW's ROE of -1.50%. Regarding short-term risk, MGRX is less volatile compared to BFRGW. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check BFRGW's competition here
MSP Recovery, Inc. (NASDAQ: LIFWZ)
MGRX vs LIFWZ Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to LIFWZ's ROE of +1.56%. Regarding short-term risk, MGRX is more volatile compared to LIFWZ. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check LIFWZ's competition here
Aclarion, Inc. (NASDAQ: ACON)
MGRX vs ACON Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, ACON has a market cap of 1.2M. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while ACON trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas ACON's P/E ratio is -0.25. In terms of profitability, MGRX's ROE is -1.06%, compared to ACON's ROE of -0.59%. Regarding short-term risk, MGRX is more volatile compared to ACON. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check ACON's competition here
Healthcare Triangle, Inc. (NASDAQ: HCTI)
MGRX vs HCTI Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, HCTI has a market cap of 990.8K. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while HCTI trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas HCTI's P/E ratio is -0.11. In terms of profitability, MGRX's ROE is -1.06%, compared to HCTI's ROE of -0.56%. Regarding short-term risk, MGRX is less volatile compared to HCTI. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check HCTI's competition here
VSee Health, Inc. (NASDAQ: VSEEW)
MGRX vs VSEEW Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, VSEEW has a market cap of 560.3K. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while VSEEW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas VSEEW's P/E ratio is -0.04. In terms of profitability, MGRX's ROE is -1.06%, compared to VSEEW's ROE of -4.01%. Regarding short-term risk, MGRX is less volatile compared to VSEEW. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check VSEEW's competition here
MSP Recovery, Inc. (NASDAQ: MSPRZ)
MGRX vs MSPRZ Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to MSPRZ's ROE of +1.56%. Regarding short-term risk, MGRX is less volatile compared to MSPRZ. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check MSPRZ's competition here
VSee Health, Inc. (NASDAQ: VSEE)
MGRX vs VSEE Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, VSEE has a market cap of 249.7K. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while VSEE trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas VSEE's P/E ratio is -0.03. In terms of profitability, MGRX's ROE is -1.06%, compared to VSEE's ROE of -4.01%. Regarding short-term risk, MGRX is less volatile compared to VSEE. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check VSEE's competition here
Akerna Corp. (NASDAQ: KERN)
MGRX vs KERN Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas KERN's P/E ratio is -0.01. In terms of profitability, MGRX's ROE is -1.06%, compared to KERN's ROE of -0.20%. Regarding short-term risk, MGRX is less volatile compared to KERN. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check KERN's competition here
Akerna Corp. (NASDAQ: KERNW)
MGRX vs KERNW Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas KERNW's P/E ratio is -0.00. In terms of profitability, MGRX's ROE is -1.06%, compared to KERNW's ROE of -0.20%. Regarding short-term risk, MGRX is less volatile compared to KERNW. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check KERNW's competition here
MSP Recovery, Inc. (NASDAQ: LIFWW)
MGRX vs LIFWW Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas LIFWW's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to LIFWW's ROE of +1.56%. Regarding short-term risk, MGRX is more volatile compared to LIFWW. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check LIFWW's competition here
CareMax, Inc. (NASDAQ: CMAXW)
MGRX vs CMAXW Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas CMAXW's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, MGRX is more volatile compared to CMAXW. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check CMAXW's competition here
Zhongchao Inc. (NASDAQ: ZCMD)
MGRX vs ZCMD Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, ZCMD has a market cap of 30.7K. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while ZCMD trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas ZCMD's P/E ratio is -0.03. In terms of profitability, MGRX's ROE is -1.06%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, MGRX is more volatile compared to ZCMD. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check ZCMD's competition here
Aclarion, Inc. (NASDAQ: ACONW)
MGRX vs ACONW Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, ACONW has a market cap of 13.8K. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while ACONW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas ACONW's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to ACONW's ROE of -0.59%. Regarding short-term risk, MGRX is less volatile compared to ACONW. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check ACONW's competition here
Change Healthcare Inc. (NASDAQ: CHNGU)
MGRX vs CHNGU Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while CHNGU trades at $73.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas CHNGU's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, MGRX is more volatile compared to CHNGU. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check CHNGU's competition here
IMS Health Holdings, Inc. (NYSE: IMS)
MGRX vs IMS Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, IMS has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while IMS trades at $31.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas IMS's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to IMS's ROE of +0.27%. Regarding short-term risk, MGRX is more volatile compared to IMS. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check IMS's competition here
Cerner Corporation (NASDAQ: CERN)
MGRX vs CERN Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, CERN has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while CERN trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas CERN's P/E ratio is 55.84. In terms of profitability, MGRX's ROE is -1.06%, compared to CERN's ROE of +0.14%. Regarding short-term risk, MGRX is more volatile compared to CERN. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check CERN's competition here
Affymetrix, Inc. (NASDAQ: AFFX)
MGRX vs AFFX Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, AFFX has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while AFFX trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas AFFX's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, MGRX is more volatile compared to AFFX. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check AFFX's competition here
MSP Recovery, Inc. (NASDAQ: MSPRV)
MGRX vs MSPRV Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while MSPRV trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas MSPRV's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to MSPRV's ROE of N/A. Regarding short-term risk, MGRX is less volatile compared to MSPRV. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check MSPRV's competition here
CareCloud, Inc. (NASDAQ: MTBC)
MGRX vs MTBC Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while MTBC trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas MTBC's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to MTBC's ROE of +0.19%. Regarding short-term risk, MGRX is less volatile compared to MTBC. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check MTBC's competition here
CareCloud, Inc. (NASDAQ: MTBCO)
MGRX vs MTBCO Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while MTBCO trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas MTBCO's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to MTBCO's ROE of +0.17%. Regarding short-term risk, MGRX is more volatile compared to MTBCO. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check MTBCO's competition here
CareCloud, Inc. (NASDAQ: MTBCP)
MGRX vs MTBCP Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while MTBCP trades at $26.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas MTBCP's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, MGRX is more volatile compared to MTBCP. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check MTBCP's competition here
Convey Health Solutions Holdings, Inc. (NYSE: CNVY)
MGRX vs CNVY Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while CNVY trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas CNVY's P/E ratio is -71.50. In terms of profitability, MGRX's ROE is -1.06%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, MGRX is more volatile compared to CNVY. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check CNVY's competition here
NantHealth, Inc. (NASDAQ: NH)
MGRX vs NH Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, NH has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while NH trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas NH's P/E ratio is -0.12. In terms of profitability, MGRX's ROE is -1.06%, compared to NH's ROE of +0.35%. Regarding short-term risk, MGRX is less volatile compared to NH. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check NH's competition here
Alkuri Global Acquisition Corp. (NASDAQ: KURIU)
MGRX vs KURIU Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, KURIU has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while KURIU trades at $9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas KURIU's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to KURIU's ROE of +1.06%. Regarding short-term risk, MGRX is less volatile compared to KURIU. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check KURIU's competition here
Sema4 Holdings Corp. (NASDAQ: SMFRW)
MGRX vs SMFRW Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while SMFRW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas SMFRW's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to SMFRW's ROE of -0.39%. Regarding short-term risk, MGRX is less volatile compared to SMFRW. This indicates lower risk in terms of short-term price fluctuations for MGRX.Check SMFRW's competition here
Change Healthcare Inc. (NASDAQ: CHNG)
MGRX vs CHNG Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while CHNG trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas CHNG's P/E ratio is -152.72. In terms of profitability, MGRX's ROE is -1.06%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, MGRX is more volatile compared to CHNG. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check CHNG's competition here
Castlight Health, Inc. (NYSE: CSLT)
MGRX vs CSLT Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, CSLT has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while CSLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas CSLT's P/E ratio is -37.27. In terms of profitability, MGRX's ROE is -1.06%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, MGRX is more volatile compared to CSLT. This indicates higher risk in terms of short-term price fluctuations for MGRX.Check CSLT's competition here
Nava Health MD, LLC (NASDAQ: NAVA)
MGRX vs NAVA Comparison September 2026
Mangoceuticals, Inc. (NASDAQ: MGRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 6.6M. In comparison, NAVA has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.39 on the NASDAQ, while NAVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.29, whereas NAVA's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.06%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, MGRX is not fully comparable compared to NAVA. This indicates unavailable risk data in terms of short-term price fluctuations for MGRX.Check NAVA's competition here